In this study, we applied a high-sensitivity MAPPs workflow using magnetic bead-based HLA-DR/DP/DQ immunoprecipitation and high-resolution mass spectrometry (HRMS) to assess the immunogenicity risk of six marketed mAbs across a panel of 10 HLA-typed donors.
